CA2028557A1 - Triazolyl hydrazide derivatives and process for their preparation - Google Patents
Triazolyl hydrazide derivatives and process for their preparationInfo
- Publication number
- CA2028557A1 CA2028557A1 CA 2028557 CA2028557A CA2028557A1 CA 2028557 A1 CA2028557 A1 CA 2028557A1 CA 2028557 CA2028557 CA 2028557 CA 2028557 A CA2028557 A CA 2028557A CA 2028557 A1 CA2028557 A1 CA 2028557A1
- Authority
- CA
- Canada
- Prior art keywords
- general formula
- formula
- group
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 125000001425 triazolyl group Chemical group 0.000 title claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 36
- 239000001257 hydrogen Substances 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims abstract description 25
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000003257 anti-anginal effect Effects 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 7
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 239000001301 oxygen Substances 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 239000011593 sulfur Substances 0.000 claims abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 102
- 235000013350 formula milk Nutrition 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 68
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 44
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 24
- -1 morpholino, methylthio, dimethylamino Chemical group 0.000 claims description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- 238000007792 addition Methods 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 150000002429 hydrazines Chemical class 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229940086542 triethylamine Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000006317 isomerization reaction Methods 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- 239000000243 solution Substances 0.000 description 15
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 10
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229960004592 isopropanol Drugs 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- WLDRFJDGKMTPPV-UHFFFAOYSA-N 1,2-dimethylhydrazine dihydrochloride Chemical compound Cl.Cl.CNNC WLDRFJDGKMTPPV-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- LJTFFORYSFGNCT-UHFFFAOYSA-N Thiocarbohydrazide Chemical compound NNC(=S)NN LJTFFORYSFGNCT-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229960001989 prenylamine Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 description 1
- OVZABHDPOBOEQH-UHFFFAOYSA-N 1-amino-1-methyl-3-(3-morpholin-4-yl-1h-1,2,4-triazol-5-yl)thiourea Chemical compound N1C(NC(=S)N(N)C)=NC(N2CCOCC2)=N1 OVZABHDPOBOEQH-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- 229940057952 methanol Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 229960005088 urethane Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
NOVEL TRIAZOLYL HYDRAZIDE DERIVATIVES AND PROCESS FOR
THEIR PREPARATION
A b s t r a c t This invention relates to novel triazolyl hydrazide derivatives and a process for the preparation thereof.
The new triazolyl hydrazide derivatives of the general formula (I), (I) wherein Q represents hydrogen or a heterocyclic group optionally substituted by a C1-4 alkyl group; or a group of the formula SR1, wherein R1 stands for C1-4 alkyl or phenyl-(C1-4 alkyl), or a group of the formula NR2R3, wherein R2 and R3 each represent hydrogen, straight or branched chained C1-6 alkyl or C2-6 alkenyl;
Z represents hydrogen or a group of the formula (C=X)-(N-R4)-NR5R6, wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or C1-4 alkyl;
R7 denotes hydrogen, C1-4 alkyl or phenyl-(C1-4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6, and pharmaceutically acceptable acid addition salts thereof exert valuable antianginal and/or gastric ulcer inhibiting properties and are useful in therapy.
THEIR PREPARATION
A b s t r a c t This invention relates to novel triazolyl hydrazide derivatives and a process for the preparation thereof.
The new triazolyl hydrazide derivatives of the general formula (I), (I) wherein Q represents hydrogen or a heterocyclic group optionally substituted by a C1-4 alkyl group; or a group of the formula SR1, wherein R1 stands for C1-4 alkyl or phenyl-(C1-4 alkyl), or a group of the formula NR2R3, wherein R2 and R3 each represent hydrogen, straight or branched chained C1-6 alkyl or C2-6 alkenyl;
Z represents hydrogen or a group of the formula (C=X)-(N-R4)-NR5R6, wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or C1-4 alkyl;
R7 denotes hydrogen, C1-4 alkyl or phenyl-(C1-4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6, and pharmaceutically acceptable acid addition salts thereof exert valuable antianginal and/or gastric ulcer inhibiting properties and are useful in therapy.
Description
Ji ~J
NOVEL TRIAZOLYL HYDRAZIDE DERIVATIVES AND PROCESS FOR
THEIR PREPARATION
This invention relates to novel triazolyl hydrazide deriva-tives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of then for the treatment of diseases and also for the preparation of pharmaceutical compositions sui-table for the treatment of said diseases.
According to an aspect of the present invention there are provided new -triazolyl hydrazide derivatives of the general formula (I) and pharmaceutically acceptable acid addition salts thereof, R7 z /N~-~N
R8 1 ~
N Q
wherein ~ Q represents hydrogen or a heterocyclic group optionally : substituted by a Cl 4 `alkyl group; or a group of the ; formula SRl, wherein Rl stands for Cl_4 alkyl or phenyl-(Cl 4 alkyl), or a group of the formula NR R , wherein R2 and R3 each represent hydrogen, straight or branched chained C1~6 alkyl or C2_6 alkenyl;
A 4696-62-PT-nz ;
u~ J
Z represents hydrogen or a group of the ~ormula (C=X)-(N-R )-NR R , wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or Cl ~ alkyl;
R7 denotes hydrogen, Cl 4 alkyl or phenyl-(Cl 4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6.
The invention encompasses all the isomers or tautomeric fnrms of the compounds of the general formula ` (I).
The new compounds according to the present invention exhibit excellent biological activity and low toxicity, e.g. they possess antianginal, tranquillant-sedative, ` 20 cardiovascular, acid secretion inhibiting, gastric ulcer ,i~ inhibiting and antimicrobial properties and -they can be used as startiny materials of other pharmaceutically ;` ~ active derivatives as well.
; The term "heterocyclic group" used throughout the specification relates -to 4 to B membered he-terocyclic groups which can be formed from compounds comprising in-dependen-tly one or more nitrogen and/or oxygen atom(s) or a group which can be obtained by condensing the same compounds with each other or with benzene. Such groups may ~ ~ 30 be aromatic or partially or completely saturated and may `~ ~ carry one or more substituent(s).
As examples for such groups e.g. the piperidyl, morpholinyl, piperazinyl, furyl, imidazolyl, pyridyl, py-rimidinyl, pyrrolyl, pyrazolyl, pyridazinyl, isoxazolyl, pyrrolinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, ~ `~
,, .
`
pyrazolidinyl, pyrazolinyl, pyranyl or del-ta-3-piperidin-l-yl groups are mentioned.
The term "alkyl group" relates to straight or branched chained saturated aliphatic hydrocarbon groups comprising 1 to 4 or 1 to 6 carbon atom(s), e.g. methyl, ethyl, i-butyl, t-butyl, n-hexyl, octyl, etc.
As C2_6 alkenyl" groups straight or branched chained alkenyl groups are mentioned (e.g. vinyl, allyl, 2-methyl-allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-bu-tenyl, 2-pentenyl, 2-hexenyl etc.).
The -term "halogen" encompasses the fluorine, chlorine, bromine and iodine atoms.
Compounds of the general formula (I), wherein Q
represents morpholino, me-thylthio, dimethylamino or N-me-thyl-piperazinyl and R7 and R8 each stand for hydrogen, and pharmaceutically acceptable acid addition salts there-of possess particularly valuable pharmaceutical proper-ties.
Particularly preferred representatives of the com-pounds of the general formula (I) are the following deri-vatives:
1-(5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N-me-thyl-carbo-thiohydrazide, 1-(5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbo-thiohydrazide, 1-(5-amino-3-N-methylpiperazinyl-lH-1,2,4--triazol-1-yl)-carbothiohydrazide, 1-(5-amino-3-morpholino-lH-1,2,4--triazol-1-yl)-N,N'-di-methyl-carbothiohydrazide 3 and pharmaceutically acceptable acid addition salts thereof.
The compounds of the general formula (I) are or-ganic bases, so they can be transformed into acid addition salts. The pharmaceutically acceptable acid addition salts of the compounds of the general formula (I) can be formed .
~ ~i3 ~ g ~
with inorganic or organic acids. As examples for the phar-maceutically acceptable acid addition sal-ts the hydroha-lides (such as hydrochlorides or hydrobromides), carbo-nates, sufates, acetates, fumarates, maleates, citrates, ascorbinates and -tartrates can be mentioned.
According to a further aspec-t of the present in-vention there is provided a process for -the prepara-tion of compounds of the general formula (I) and pharmaceutically acceptable acid addition salts thereof, with comprises a) reacting a triazolyl ester of the general formula (II), R7 y lO~ N
N
( 11 ) wherein Y represents hydrogen or a group of the formula ~ (C=X)-XR9, wherein X is as stated above, R9 is -~ C1 4 alkyl or phenyl optionally substi-tuted by one or more halogen atom(s), R and Q are as defined above, RlO represents hydrogen or a group of the formula (C=X)-XR9, with the proviso that if Y stands for hydrogen, RlO represents a group of the formula (C=X)-XR9, wherein X and R9 are as stated above, and if Y stands for a group of the formula (C=X)-XR9, R10 represents hydrogen, with a hydrazine derivative of the general formula (III), .
- ~ -. '-i HN - N - R6 ( 111 ) :.
10wherein R4, R5 and R6 are as stated above, or b) for the preparation of isomeric compounds of the gen-eral formulae (Ib), (Ic) and (Id) representing subyroups of the compounds of the general formula (I), R7- N ~ R7-N ~ N~N,C~N ~ N - R6 R6-N - N-C ~ N Q N ~ Q
(Ib) (Ic) R6--N--~ N~H
` N
~ 30 (Id) ,:
' :
~: 35 ', , -. , . ~
.
.
2 ~ 2 ~
reacting a triazolyl ester of the general formula (IIa), X
Il R7-H ~ N~
Q
. ~
( lla) wherein R7, R9, X and Q are as stated above, with a hydrazine derivative of the general formula : (III), heating the thus-obtained compound of the general for-mula (Ia), , C--N--N--R6 ` N
~, ( 1~1 ` 25 and separating the isomers from each other by methods known per se; or ~ c) for the preparation of isomeric compounds of the gen-: eral formulae (Ib), (Ic) and (Id) representing subgroups `~ of the compounds of the general formula (I), heating a compound of the general formula (Ia) and separating the ~; isomers from the ~thus-obtained product by methods known per se; or . d) for the preparation of compounds of the general formula (Ia) representing a subgroup of the compounds of the general formula (I), wherein R4, R5, R6 and R7 repre-.
:
~ J
sent hydrogen and Q stands for a group of -the formula SR11, wherein R11 deno-tes C1 ~ alkyl or phenyl-(Cl ~
alkyl) optionally bearing one or more halogen, C1 4 al-kyl or nitro substituent (s), reacting a compound of the general formula (IV), (IV) wherein X is as stated above, wi-th a compound of -the general formula (V), NC- N-C~ SRll, SRll (V ) wherein Rll is as s-ta-ted above;
and, if desired, converting the compound of the general formula (I) thus-obtained into a pharmaceutically acceptable acid addition salt thereof or setting free a base of -the general formula (I) from an acid addi-tion salt thereof, or converting an acid addition salt of a : base of the general formula (I) in-to ano-ther acid addi-tion salt.
The reac-tion of the compounds of the general for-mulae (II) and (IIa), respectively, with hydra7ine ~ ~ 1! 6'~ 3 ~ ~ ~ J
derivatives of the general formula (III) is carried ou-t in a solvent inert toward the reactants. For this purpose pre-ferably methanol, 2-propanol, benzene or dimethyl sulfo~id are used. The reaction is performed at a temperature of 0 to 190 C, preferably between 20 and 110 C. The reaction is op-tionally carried ou-t in the presence of a base, pre-ferably an organic base.
The isomerisation of the compounds of the general formula (Ia) into compounds of the general formulae (Ib), (Ic) and (Id) can be carried out in melt or by thermic rearrangenent in a polar or dipolar aprotic solvent, pre-ferably in acetic acid or dime-thylformamide, a-t a temperature between 50 C and 250 C, preferably a-t a temperature of lOO to 190 C. During the reaction a mixture of the compounds of the general formulae (Ib)~
(Ic) and (Id) is produced, which can be separated into the individual isomers by methods known per se, e.g. by chro-; matography or fractional crystallization.
The reaction of the compounds of the general for-mulae (IV) and (V) can be performed in a polar solvent,preferably in an aqueous methanol solution, dimethylform-amide or dimethyl sulfoxide, at a -temperature between 0 and 190 C, preferably at a temperature of 50 to 160 C.
The compounds of the general formula (I) obtained in form of a base can be converted into acid addition salts by methods known per se. For this purpose the free bases are reacted with the corresponding acid in an inert solvent.
The triazolyl esters of the general formula (II) used as starting ma-terials are known compounds or can be produced on the analogy of known compounds (US patent specification No. 3,686,301, DD pa-tent specification No.
105,~97).
The hydrazine derivatives of the general formula (III) are also known compounds (Belsteins Handbuch der Or-~ J~
_9_ ganischen Chemie 4, 546, Verlag Springer, Berlin, 1922;Ullmann: Encyklopadie dEr Technischen ~hemie 13, p. 95, Verlag Chemie Weinheim, 1977).
The carbohydrazide and thiocarbohydrazide of the general formula (IV) are commercially available products.
The compounds o~ the general formula (V) are also commercial products or can be prepared as described in Hungarian patent specification No. 184,743.
The compounds of the general formula (I) are only very slightly toxic and show excellent biological proper-ties. They exert antianginal, tranquillant-sedative, car-diovascular, acid secretion inhibiting, gastric ulcer in-hibiting and antimicrobial ef~ec-ts.
The ac-tivity of the compounds of the general for-mula (I) has been examined by the following tests.
1. ~ntianginal effect Method: Nieschulz, E., Popendiker, K. and Hoffmann, I., Arzneimittel-Forschung, 5, 680 (1955) The -test was carried ou-t on rats weighing 180 to 220 9. The animals were narcotised with chloralese-ure-thane (70 - 700 mg/kg ip.). The ECG was registered with needle electrodes in standard II leading. The experimen-tal coro-naria insufficiency was induced with vasopressin (1 NE/kg ; 25 i.v.). The height of wave T was measured before and after the administration of vasopressin in both the control and treated groups. Test compounds were administered intra-venously 2 minutes prior to the trea-tmen-t with vasopressin The results are summarized in Table I.
Table I
Antianginal e~fect Test compound ED50 mg/kg (Example No.) (iv.) :
..
' ` ' AJ
-17 0.84 Prenylamine 6.5 2. Motility inhibiting activity Method: Borsy, J., Csanyi, E., Lfizar, I.: Arch. Int.
Pharmacodyn. 124, 1-2 (1960) The tests were performed on mice. Groups consisting of 3 mice each were trated perorally with different doses of the compounds to be tested. One hour after -the admi-nistration the test animals were placed in a Dews equip-ment. In this equipment the number of interruptions of ~; 15 infrared beam within 30 minutes was counted. The results :~i obtained are shown in Table II.
:, ` Table II
Mo-tility inhibiting ef~ect Compound LD50 Therapeutical ~ (Example No.) mg/kg p.o. index - 1 100 ~ 10 17 70 ~ 5 - Meprobamate270 4.1 3. Acute toxicity on mice Method: Litchfield, J.T., Wilcoxon, ~.W.: Pharmacol. Exp.
Ther., 96, 99 (1949) White mice belonging -to the CFLP strain (body weight 18 to 22 9, both male and female) were used, 6 animals for each dose. The test compounds were administered orally in a volume of 20 ml/kg. After treatment the animals ' ' , ~ jJ ,~ ~? I , ; 1 were observed for a period of 14 days. The mice ~ere kep-t in a plastic cage at room temperature. The animals get tap wa-ter and s-tandard mouse fodder ad libi-tum. The toxicity data were determined with the aid of the method of Litchfield and Wilcoxon. The results are summarized in Table III.
Table III
Acute toxicity on mice Example No. Ld50 mg/kg p.O.
16 lO00 l ~ lO00 9 lO00 The above data show that certain representatives of the compounds according to the invention are 8 or 10 times as effective on the antianginal test as the re-ference substance Prenylamine and are superior as motility inhibi-tors to the reference compound Meprobamate. At the sametime they are only very slightly toxic.
In addition, the compounds according to the in-vention possess valuable antimicrobial effect, especially against nonfermenting Gram-negative bacteria strains. So the compound of Example 9 inhibits, determined by agar diffusion method in a concentration of 500 /ug/hole, the bacteria strains listed in Table IV.
:
` Table IV
An~timicrobial e~ffect of the compound according -to Ex. 9 .
~ J~ 5 Microbe strain HNCMB+ Inhibition (%) deposition number Salmonella enteritidis 10091 17 Shigella sonnei 20046 19 Acinetobacter calcoaceticus 150001 20 Pseudomonas aeruginosa 170006 14 Pseudomonas stutzeri 173008 25 Alcaligenea faecalis 140001 23 HNCMB = Hungarian National Collection of Medical Bacteria 4. Stomach-secretion and ulcus tes-ts on mice Method: 5hay, H., Komarov, S.A., ~els. 5.5., Meranze, O., Gruenstein, M., Siplet, H.: Gas-troenterology 5, 45 (1945); Adami, E., Marazzi-Ubertti, E., Tirba, C.: Arch. Int. Pharmacodyn. 147, 113 (1964).
Starved wistar mice of 150-250 9 body weight were used, 4 male and 4 female animals for each dose. On the day of the experiment the pylorus of the animals was ligatured under ether narcosis. The doses of the test compounds were administered per os, 3 hours before the operation. The control groups were treated with the carrier in identical way. 4 hours after -the operation the 'animals were over-narcotized wi-th ether, their stomach was removed, the stomach contents were separa-ted and after centrifugation the volume of -the gas-tric juices was - measured, then their free-acid content and to-tal acidity, resp., were determined by titra-tion wi-th 0.1 N NaDH sol-ution. The changes of the gastric mucous membrane were investigated macroscopically and characteri~ed by an ulcus `;
J t ,) ? ,'~
index determined with -the aid of the punctuation method of Adami and coworkers.
The results obtained are shown in Table V.
Table V
Gastric-secretion- and ulcus-inhibiting effects on mice Example Dose Inhibition related to the cnntrol in %
No. mglkg Gastric Free Total Ulcus po. juice acid acidity index :
Cimetidine50 22 24 15 18 :
The above data unambiguously show that the effect of the compounds according to the invention reach or even surpasse that of Cimetidine but their toxicity is slight and due to the differing structures they are exempt from the very unfavcurable side-effect of causing impotency of Cimetidine.
According to a ~urther aspect of the present in-vention there are provided pharmaceutical compositions comprising as active ingredient at least one compound of the general formula (I) or a pharmaceutically acceptable -: acid addition salt thereof in admixture with suitable : 30 inert solid or liquid pharmaceutical carriers.
The pharmaceutical compositions of the present in-vention can be prepared by methods.known ~ se by ad-mixing the active ingredient with suitable inert solid or liquid carriers and bringing the mixture to galenic form.
The pharmaceutical compositions of the presen-t in-.- ~ .
vention may be suitable for oral (e.g. tablet, pill, coated pill, dragée, solid or soft gelatine capsule, solution, emulsion or suspension), parenteral (e.g.
injection solution) or rectal (e.g. suppository) admi-nistration.
As carrier for the preparation of tablets, coa-ted tablets, dragées and solid gelatine capsules e.g. lactose, corn starch, potatoe starch, talc, magnesium carbonate, magnesium stearate, calcium carbonate, stearic acid or the salts thereof, etc. can be used. As carrier for the soft gelatine capsules e.g. vegetable oils, :Eats, waxes or po-lyols of suitable consistency can be used. As carriers for the solutions and syrups e.g. water polyols (polye-thy].ene glycol),saccharose or glucose can be used. The injection solutions can comprise e~g. water alcohols, polyols, glycerol or vegetable oils as carrier. The suppositories can be prepared with the aid of e.g. oils, waxes, fats or polyols of suitable consistency.
In addition, the pharmaceutical formulations may comprise auxiliaries usually applied in pharmaceutical industry, e.g. wetting, sweetening agents, aroma substances, salts causing the change of osmotic pressure, buffers, etc.
The compounds of the general formula (I) can prefer-ably be used in -therapy orally in the form of tablets or capsules. Especially preferred are the capsules or tablets comprising 0.5 to 500 mg of active ingredient The daily dose of the compounds of the general for-mula (I) can vary within wide ranges depending on several factors, e.g. on the activity of the active ingredient, the patient`s condition and age, the severity of the disease, etc. The oral dose is generally 2 to 5000 mg/day, preferably 5 to 1000 mg/day. It has to be stressed tha-t the above dose is only of informative character and the administered dose must always be determined by the , . . . ' ,'. . ' .
physician thera~eutist.
AccQrding to a further aspect of the present in-vention there is provided the use of the compounds of the general formula (I) or pharmaceutically acceptable salts thereof for the preparation of pharmaceutical compositions having par-ticularly antianginal and/or gas-tric ulcer in-hibiting effects.
According to a still fur-ther aspect of the present invention there is provided a method for antianginal and/or gastric ulcer inhibiting treatment, which comprises ad-ministering to the patient an effective amount of a com-pound of the general formula tI) OL' a pharmaceutically acceptable salt thereof.
The invention is fur-ther il-lustra-ted by the aid of the following Examples of non-limiting character.
Example 1 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4--triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. Then the separated crys-tals are filtered off and recrystallized from benzene.
Yield: 15.0 q (59 %) M.p.: 144 to 146 C.
E~ample 2 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N'-methyl-carbothiohydrazide One proceeds as described in Example 1, with the difference that the mother liquor obtained after filtering the reaction mixture is allowed to stand for 2 days. The separated crystals are then filtered off and recrystallized . .
, . . -~. . . j . .
~ J ~ $ e~ ?~
from 2-propanol.
Yield: 3.8 9 (15 %) M.p.: 125 to 126 C.
Example 3 1-(5-Amino-3-morpholino-lH-192,4-triazol-l-yl)-N-methyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 100 ml 10 of dimethyl sulfoxide, in the presence of 5.7 ml (0.11 mole) of methylhydrazine for 8 hours at room temperature.
The reaction rnixture is poured onto 100 ml of water, the separated crystals are filtered off and recrystallized from benzene.
15 Yield: 8.3 9 (38 %) M.p.: 144 to 146 C.
Example 4 - 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl3-N-me-thyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio~
lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separa-ted crystals are filtered off and recrystallized from benzene.
Yield: 11.8 g (54 %) M.p.: 164 to 166 C.
:
Example 5 1-(5-Amino-3-methylthio-lH-1,2,4-triaznl-1-yl)-N-methyl-oarbothiohydrazide 22.0 g (0.1 mole) of methyl (5-amino-3-methyl-thio-1_-1,2,4-triazol-1-yl)carbodithioate are stirred in 400 ml of 2-propanol, in the presence of 6.9 ml (0.13 mole) of ~ - -, . .
.
.
` ~ d J '~
$ æY
methylhydrazine for 8 hours at room -temperature. The separated crystals are filtered off and recrys-tallized from benzene.
Yield: 10.5 9 (4B %) M.p.: 164 to 166 C.
Example 6 1-~5-Amino-3-me-thylthio-lH-1,2~4-triazol-1-yl)-N-me-thyl-carbothiohydrazide 22.0 9 (0.1 mole) of me-thyl (5-amino-3-me-thylthio-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 200 ml of benzene, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 8 hours a-t room temperature. The separated crystals are fil-tered off and recrystallized from benzene.
Yield: 8.9 9 (41 ~) M.p.: 164 to 166 C.
.
Example 7 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 11.8 9 (54 %) M.p.: 164 to 166 C.
Example 8 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl~-N-methyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1~2,4-triazol-1-yl)carbodithioate are boiled in 140 ml . .
. . .
:, .
~ ~; 2 ~
of methanol, in the presence of 5.7 ml (0.11 mole) of methylhydrazine for 1 hour. The reac-tion mixture is then evaporated to 70 ml, the separated crystals are filtered off and recrystallized from benzene.
Yield: 8.3 9 (3a %) M.p.: 164 to 166 C.
Example 9 1-~5-Amino-3-N-methylpiperazinyl)-lH-1,2 9 4-triazol-l-yl~-N-methyl-carbothiohydrazide 27.2 g (0.1 mole) of methyl (5-amino-3-N-methylpi-perazinyl-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours. The reac-tion mix-ture is evaporated to dryness in vacuo. The oily product thus obtained crystallises upon adding of 2-propanol. The se-para-ted crystals are filtered off and recrystallized from acetonitrile.
Yield: 13 9 (48 %) M.p.: 150 to 152 C.
Example 10 1-(5-Amino-3-dimethylamino-lH-1,2,4-triazol-1-yl)-N-me~hyl-carbothiohydrazide 21.7 g (0.1 mole) of methyl. (5-amino-3-dimethyl-amino-1~1-1,2,4-triazol-1-yl)carbodithioate are stirred in 100 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at roorn temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 12.2 9 (51 %) M.p.: 165 ta 167 C.
Example 11 1-(5-Ami~o-3-mo~pholirlo-4H-1,2,~ riazol-4-yl)-N-. ~
, ', ~, ' ' ' ~- , . ' ~
r methyl-carbothiohydrazide 25.5 9 (0.1 mole) of 1-(5-amino-3-morpholino-lH-`- 1,2,4-triazol-1-yl)~N-methyl-carbodithiohydrazide areboiled in 75 ml af acetic acid for 30 minutes, under stirring. The reaction mixture is cooled, the separated crystals are filtered off and recrystallized from ; methanol.
Yield: 10.5 9 (41 %) M.p.: 239 to 240 C.
Example 12 1-(5-Amino-3-morpholino-2H-1,2,4-triazol-2-yl)-N-methyl-carbothiohydrazide On proceeding as described in Example 11 the mother liquor ob-tained after filtering the reaction mixture is evaporated to dryness and the residue is recrys-tallized first from an aqueous ethanol solution then from aceto-nitrile.
Yield: 6.12 9 (24 %) M.p.: 258 to 259 C.
.
Example 13 2-Methyl-4-(3-morpholino-lH-1,2,4--triazol-5-yl) thiosemicarbazide 25.7 9 (0.1 mole) of methyl (3-morpholino-2H-1,2,4-~ triazol-5-yl)dithiocarbaminate are boiled in 250 ml of ;~ methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 2 hours, under s-tirring. The separated crystals are filtered off and recrystallized from methanol.
Yield: 17.34 9 (68 %) M.p.: 211 to 212 C.
Exa~ple 14 (5-Benzylamino-3-morpholino-lH-1,2,4-triazol-1-~5 yl)-N-me-thyl-carbothiohydrazide 34.9 9 (0.1 mole) o~ methyl (5-benzylamino-3-, ~, , ', 2 ~ 2 ~ 'J
morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 22.5 9 (63 %) M.p.: 133 to 134 C.
Example 15 1-~5-Benzylamino-3-morpholino-lH-1,2,4-triazol 1-yl)-N'-methyl-carbothiohydrazide One proceeds as described in Example 14, wlth the difference that the mother liquor obtained after filtra-tion is allowed to stand for 2 days. Then the separated crystals are filtered off and recrystallized from a mixture of n-hexane and ether.
Yield: 5.6 9 (16 %) M.p.: 86 to 87 C.
Example 16 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl) carbothiohydrazide A mixture of 25.7 g (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate, 2ûO ml of methanol and 6 ml (0.12 mole) o~ a 99 % hydrazine hydrate solution is stirred for 4 hours at room temperature. Then it is filtered and the ~thus-obtained crystals are recrystallized from a mixture of dime-thyl-formamide and acetonitrile.
Yield: 20.9 9 (86 %) M.p.: 180 to 18Z C.
Example 17 1-~5-Amino-3-me-thylthio-lH-1,2,4-triazol-1-yl) carbothioh~drazide . ;
.
` . ~
':
~ ~ ~ C,,~ ~; ?'~ rJ
A mixture of 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbodithioate, 200 ml of methanol and 6 ml (0.12 mole) of a 99 % hydrazine hydrate solution is stirred for 4 hours at room J
temperature. Then it is filtered and the precipitated crystals are recrystallized from dimethyl~ormamide.
Yield: 17.3 9 (85 %) M.p.: 185 to 186 C.
Example 18 1-(5-Amino-~-methylthio-lH-1,2,4-triaznl-1-yl) carbo-thiohydrazide To a mixture of 10.6 9 (0.1 mole) of thiocarbohydrazide and 130 ml of water a solution of 15 9 (0.102 mole) of dimethyl (N-cyanocarbonimidodithioate) in 65 ml of methanol is added, and the reaction mixture is m boiled for 2 hours. Then it is cooled, the precipitated crystals are filtered off and recrystallized from dime-thylformamide.
Yield: 17.8 9 (86 %) M.p.: 185 to 186 C.
Example 19 1-~5-Amino-~-(N-methylpiperazinyl~-lH-1,2,4-triazol-l-yl~carbothiohydrazide 27.2 9 (0.1 mole) of methyl ~5-amino-3-(N-methyl-~ piperazinyl)-lH-1,2,4-triazol-1-yl)carbodithioate are -~ stirred in 150 ml of methanol, in the presence of 6.9 ml ~0.13 mole) of hydrazine hydrate for 4 hours at room temperature. Then the reaction mixture is cooled and the -thus-obtained crystals are recrystallized from dimethyl-formamide.
Yield: 24.5 9 (94 %) M.p.: 194 to 196 C.
'~
, .
~ - :
$ i~ ~
Preparation of the trihydrochloride salt:
1 9 of base ob-tained as described above is dissolved in 5 ml of hot dimethylformamide, and the solution is acidified to pH=2 with a 15 % (v/v) solution o~ hydrogen chloride in isopropanol. The separated product is filtered off and washed with isopropanol.
Yield: 0.9 9 M.p.: 158 to 160 C.
Example 20 1-(5-Amino-3-morphnlino-lH-1,2,4-triazol-1-yl)-N,N'-dimethyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are boiled in 1~0 ml of methanol, in the presence of 14.6 ml (0.12 mole) of N,N'-dimethylhydrazine dihydrochloride and 46 ml of tri-ethylamine for 16 hours. Then the reaction mixture is evaporated to dryness in vacuo. 400 ml of water are added to the residue and the aqueous phase is extracted three times with 200 ml of chloroform. The organic phase thus obtained is washed two times with 200 ml of water, dried over magnesium sulfate and evaporated in vacuo. The precipitated crystals are suspended in diethyl ether and fil-tered off.
Yield: 11.3 y (43 %) M.p.: 127 -to 128 C.
Example ~1 1-(5-Amino-3-diallylamino-lH-1,2,4-triazol-1-yl)-N-me~hyl-carbothiohydrazide 4.2 9 (0.0156 mole) of methyl (5-amino-3-diallyl-amino-lH-1,2,4-triazol-1-yl)carbodithioa-te and 1~38 ml (0.026 mole) of methylhydrazine are reacted in 20 ml of methanol at room temperature for 8 hours. Upon adding 10 ml of water to the thus-ob-tained solution 1.2 9 (29 %) of ' pure 1-(5-amino-3-diallylamino-lH-1,2,4--triazol-1-yl)-N-methyl-carbothiohydrazide get separated. M.p.: 86 to B8 C. When evaporating the mother liquor further 2 9 of crystalline product are obtained which melt at 85 to 88 C
So the total yield amounts to 77 %.
Example 22 1-(5-Benzylamino-3-morpholino-lH-1,2,4-triazol-1-yl)-N,N'-dimethyl-carbothiohydrazide 6.9B 9 (0.02 mole) of methyl (5-benzylamino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are boiled `in 50 ml of methanol, in the presence of 2.92 ml (0.024 mole) of N,N'-dimethylhydrazine dihydrochloride and 9.4 ml of triethylamine for 8 hours. Then the reaction mixture is evaporated to dryness in vacuo. 100 ml of water are added to -the residue and the aqueous phase is extracted three times with 50 ml of chloroform. The thus-obtained organic phase is washed twice with 50 ml of water, dried over magnesillm sulfate and evapora-ted to dryness in vacuo. The thus-obtained crystals are suspended in diethyl e-ther and filtered off.
Yield: 3.25 9 (45 %) M.p.: 66 to 68 C.
Exa~ple 23 5-(4-Dimethylaminobenzylamino)-3-morpholino-lH-1,2,4-triazol-1-yl~carbothiohydrazide 1.96 9 (0 005 mole) of methyl ~5-(4-dimethylamino-benzylamino)-3-morpholino-lH-1,2,4-triazol-1-yl~carbodi-thioate are boiled in 20 ml of methanol, in the presence of 0.3 ml of hydrazine hydrate for 1 hour, under stirring.
The reaction mixture is cooled, the separated crystals are filtered off and recrystallized from methanol.
Yield: 1.43 9 (a3 %) M.p.: 127 to 129 C.
-ft ~ r~ r r Example 24 1-(4-Chlorobenzylamino-3-morpholino-lH-1,2,4-triazol-l-yl)-N-methyl-carbothiohydrazide 38.2 9 (0.1 mole) of me-thyl /5-(4-chlorobenzyl-amino)-3-morpholino-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 700 ml of methanol, in the presence of 6.4 ml (0.12 mole) of methylhydrazine for 1 hour, under stirring. The reaction mixture is cooled, the precipitated crystals are filtered off and recrystallized -from a mixture of benzene and cyclohexane.
Yield: 23.2 9 (61 %) M.p.: 152 to 154 C.
Example 25 1-/5-(4-chlorobenzylamino)-3-me-thylthio-lH-1,2,4-triazol-l-yltcarbothiohydrazide 17.2 9 (0.05 mole) of methyl /5-(4-chlorobenzyl-amino)-3-methylthio-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 200 ml of methanol, in -the presence of 6 ml of hydrazine hydrate for 0.5 hour, under stirring. The -~ reaction mixture is cooled, the separated crystals are filtered off and recrystallized from methanol.
Yield: 13.8 9 (84 %) M.p.: 140 to 142 C.
Example 26 1-(5-Benzylamino-3-morpholino-lH 1,2,4-triazQl-l~
yl)carbothiohydrazide 3.49 9 (0.01 mole) of methyl (5-benzylamino-3-mor-pholino-lH-1,2,4-triazol-1-yl)carbodi-thioate are stirred in 50 ml of methanol, in the presence of 0.64 ml (0.013 mole) of hydrazine hydrate for 4 hours, at room temperature.
The separated crystals are filtered off and recrystallized from methanol.
Yield: 2.84 9 (85 O) - . . :
..... ........ ........ ... ......... .... ..... ... ........ ............... .... ... ... ... ........... ,:
- ~ .
. : , ' ~: , -- , ~ .
,2 M.p.: 141 to 143 C.
Example 27 1-/5-(4-Chlorobenzylamino)-3-morpholino-lH-1,2,4-triazol-l-yl/carbothiohydrazide 1.9 9 (0.005 mole) of methyl /5-(4-chlorobenzyl-amino)-3-morpholino-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 40 ml of methanol, in the presence of 0.3 ml (0.0058 mole) of hydrazine hydrate for 1 hour, under stirring. Then the separated crystals are fil-tered off and recrystallized from methanol.
Yield: 2.64 9 (71 %) M.p.: 169 to 171 C.
Example 28 1-(3~5-Dîamino-lH-1,274-triazol-l-yl)-N-methyl-carbothiohydrazide 0.76 9 ~0.004 mole) of methyl (3,5-diamino-lH-1,2,4-triazol-1-yl)-N-methyl-carbodithioate is stirred in 75 ml of methanol, in the presence of 0.29 ml of hydrazine hydrate for 1 hour at room temperature. The separated crystals are filtered off and recrystallized from 2-propa-nol.
Yield: 0.68 9 (73 %) M.p.: 1~4 to 186 C.
Example 29 1-(5-Amino-3-diallyla~ino-lH-1~2,4-triazol-1-yl3 carbothiohydrazide 26.90 9 (0.1 mole) of methyl-(5-amino-3-diallyl-amino-lH-1,2,4--triazol-1-yl)carbodi-thioate are boiled in 200 ml of methanol, in the presence of 6 ml of hydrazine hydrate for 1 hour, under stirring. The precipitated crystals are filtered off and recrystallized from benzene~
Yield: 20.64 9 (82 %) : . :
: , , .
2~
M.p.: 142 to 144 C.
Example 30 1-(5-Amino-3-methyl-thio-lH-1,2,4-triazol-1-yl)-carbo-thiohydrazide To a mixture of 9 9 (0.1 mole) of carbohydrazide and 160 ml of methanol a solution of 14.6 9 (0.102 mole) of dimethyl N-cyanocarbonimidodithioate in 100 ml of me-thanol is added under stirring. The reaction mixture is boiled for 3 hours, then it is cooled, the separated crystals are filtered off and recrystallized from metha-nol.
Yield: 15.6 9 (83 %) M.p.: 163 to 164 C.
Example 31 1-(5-Amino-2H-1,2,4-triazQl-2.-yl)-N-methyl-carbothiohydrazide 0.61 9 (0.0035 mole) of 1-(5-amino-2H-1,2,4-tri-azol-2-yl)carbodithioate is stirred in lU ml of me-thanol, in the presence of 0.184 ml (0.004 mole) of methyl-~; hydrazine for 2 hours, at room temperature. The ; solution is evaporated to dryness in vacuo and the residue is recrystallized from isopropanol.
Yield: 0.4 9 (66 %) M.p.: 85 to 90 C.
Example 32 Tablets having the following composition are prepared by methods known per se of the pharmaceutical industry:
:
Compsnents Amount, g/tablet 1-(5-Amino-3-morpholino-lH-35 1,2,4-triazol-1-yl)carbothio-- . . .: .
' ' - - ' : ~: ' .. . .
r~
hydrazide 5 Lactose 1~.5 Po-tato starch 13.0 Polyvinylpyrrolidone 6.8 5 Stearic acid 2.7 Talc 4.0 Total weight 50.0 9 Example 33 Ointments having the following composition are prepared by me-thods known per se of the pharmaceutical industry:
Components Amount 15 1-(5-Amino-3-morpholino-lH-1 t 2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 500 mg : Unguentum hydrophilicium nonbonicum10 9 The active ingredient is in the outer phase of the ointment, in dissolved state.
Example 34 Suppositories having the following compositiun are prepared by methods known per se of -the pharmaceutical industry:
Components Amnunt 3 mg/suppository 1-~5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbothio-.~ hydrazide 100 Lecithin 48 Cera alba 96 Cocoa butter 1870 : 35 .~
.
rl Distilled ~ater 386 Total weight 2500 mg Example 35 `: 5 Capsules having the following composition are ; prepared by methods known per se of the pharmaceutical industry:
Components Amount, mg/capsule 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-l-yl)carbothio-hydrazide 50 Lactose Potato starch lO
Magnesium stearate Total weight 180 mg-:.
~`
:.:
~, ; :
:~ 30 :
~'Z
' .
' ~
,:-.
.
- , , :
~ : : ?
NOVEL TRIAZOLYL HYDRAZIDE DERIVATIVES AND PROCESS FOR
THEIR PREPARATION
This invention relates to novel triazolyl hydrazide deriva-tives, a process for the preparation thereof, pharmaceutical compositions comprising the same, to the use of then for the treatment of diseases and also for the preparation of pharmaceutical compositions sui-table for the treatment of said diseases.
According to an aspect of the present invention there are provided new -triazolyl hydrazide derivatives of the general formula (I) and pharmaceutically acceptable acid addition salts thereof, R7 z /N~-~N
R8 1 ~
N Q
wherein ~ Q represents hydrogen or a heterocyclic group optionally : substituted by a Cl 4 `alkyl group; or a group of the ; formula SRl, wherein Rl stands for Cl_4 alkyl or phenyl-(Cl 4 alkyl), or a group of the formula NR R , wherein R2 and R3 each represent hydrogen, straight or branched chained C1~6 alkyl or C2_6 alkenyl;
A 4696-62-PT-nz ;
u~ J
Z represents hydrogen or a group of the ~ormula (C=X)-(N-R )-NR R , wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or Cl ~ alkyl;
R7 denotes hydrogen, Cl 4 alkyl or phenyl-(Cl 4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6.
The invention encompasses all the isomers or tautomeric fnrms of the compounds of the general formula ` (I).
The new compounds according to the present invention exhibit excellent biological activity and low toxicity, e.g. they possess antianginal, tranquillant-sedative, ` 20 cardiovascular, acid secretion inhibiting, gastric ulcer ,i~ inhibiting and antimicrobial properties and -they can be used as startiny materials of other pharmaceutically ;` ~ active derivatives as well.
; The term "heterocyclic group" used throughout the specification relates -to 4 to B membered he-terocyclic groups which can be formed from compounds comprising in-dependen-tly one or more nitrogen and/or oxygen atom(s) or a group which can be obtained by condensing the same compounds with each other or with benzene. Such groups may ~ ~ 30 be aromatic or partially or completely saturated and may `~ ~ carry one or more substituent(s).
As examples for such groups e.g. the piperidyl, morpholinyl, piperazinyl, furyl, imidazolyl, pyridyl, py-rimidinyl, pyrrolyl, pyrazolyl, pyridazinyl, isoxazolyl, pyrrolinyl, pyrrolidinyl, imidazolidinyl, imidazolinyl, ~ `~
,, .
`
pyrazolidinyl, pyrazolinyl, pyranyl or del-ta-3-piperidin-l-yl groups are mentioned.
The term "alkyl group" relates to straight or branched chained saturated aliphatic hydrocarbon groups comprising 1 to 4 or 1 to 6 carbon atom(s), e.g. methyl, ethyl, i-butyl, t-butyl, n-hexyl, octyl, etc.
As C2_6 alkenyl" groups straight or branched chained alkenyl groups are mentioned (e.g. vinyl, allyl, 2-methyl-allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-bu-tenyl, 2-pentenyl, 2-hexenyl etc.).
The -term "halogen" encompasses the fluorine, chlorine, bromine and iodine atoms.
Compounds of the general formula (I), wherein Q
represents morpholino, me-thylthio, dimethylamino or N-me-thyl-piperazinyl and R7 and R8 each stand for hydrogen, and pharmaceutically acceptable acid addition salts there-of possess particularly valuable pharmaceutical proper-ties.
Particularly preferred representatives of the com-pounds of the general formula (I) are the following deri-vatives:
1-(5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N-me-thyl-carbo-thiohydrazide, 1-(5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbo-thiohydrazide, 1-(5-amino-3-N-methylpiperazinyl-lH-1,2,4--triazol-1-yl)-carbothiohydrazide, 1-(5-amino-3-morpholino-lH-1,2,4--triazol-1-yl)-N,N'-di-methyl-carbothiohydrazide 3 and pharmaceutically acceptable acid addition salts thereof.
The compounds of the general formula (I) are or-ganic bases, so they can be transformed into acid addition salts. The pharmaceutically acceptable acid addition salts of the compounds of the general formula (I) can be formed .
~ ~i3 ~ g ~
with inorganic or organic acids. As examples for the phar-maceutically acceptable acid addition sal-ts the hydroha-lides (such as hydrochlorides or hydrobromides), carbo-nates, sufates, acetates, fumarates, maleates, citrates, ascorbinates and -tartrates can be mentioned.
According to a further aspec-t of the present in-vention there is provided a process for -the prepara-tion of compounds of the general formula (I) and pharmaceutically acceptable acid addition salts thereof, with comprises a) reacting a triazolyl ester of the general formula (II), R7 y lO~ N
N
( 11 ) wherein Y represents hydrogen or a group of the formula ~ (C=X)-XR9, wherein X is as stated above, R9 is -~ C1 4 alkyl or phenyl optionally substi-tuted by one or more halogen atom(s), R and Q are as defined above, RlO represents hydrogen or a group of the formula (C=X)-XR9, with the proviso that if Y stands for hydrogen, RlO represents a group of the formula (C=X)-XR9, wherein X and R9 are as stated above, and if Y stands for a group of the formula (C=X)-XR9, R10 represents hydrogen, with a hydrazine derivative of the general formula (III), .
- ~ -. '-i HN - N - R6 ( 111 ) :.
10wherein R4, R5 and R6 are as stated above, or b) for the preparation of isomeric compounds of the gen-eral formulae (Ib), (Ic) and (Id) representing subyroups of the compounds of the general formula (I), R7- N ~ R7-N ~ N~N,C~N ~ N - R6 R6-N - N-C ~ N Q N ~ Q
(Ib) (Ic) R6--N--~ N~H
` N
~ 30 (Id) ,:
' :
~: 35 ', , -. , . ~
.
.
2 ~ 2 ~
reacting a triazolyl ester of the general formula (IIa), X
Il R7-H ~ N~
Q
. ~
( lla) wherein R7, R9, X and Q are as stated above, with a hydrazine derivative of the general formula : (III), heating the thus-obtained compound of the general for-mula (Ia), , C--N--N--R6 ` N
~, ( 1~1 ` 25 and separating the isomers from each other by methods known per se; or ~ c) for the preparation of isomeric compounds of the gen-: eral formulae (Ib), (Ic) and (Id) representing subgroups `~ of the compounds of the general formula (I), heating a compound of the general formula (Ia) and separating the ~; isomers from the ~thus-obtained product by methods known per se; or . d) for the preparation of compounds of the general formula (Ia) representing a subgroup of the compounds of the general formula (I), wherein R4, R5, R6 and R7 repre-.
:
~ J
sent hydrogen and Q stands for a group of -the formula SR11, wherein R11 deno-tes C1 ~ alkyl or phenyl-(Cl ~
alkyl) optionally bearing one or more halogen, C1 4 al-kyl or nitro substituent (s), reacting a compound of the general formula (IV), (IV) wherein X is as stated above, wi-th a compound of -the general formula (V), NC- N-C~ SRll, SRll (V ) wherein Rll is as s-ta-ted above;
and, if desired, converting the compound of the general formula (I) thus-obtained into a pharmaceutically acceptable acid addition salt thereof or setting free a base of -the general formula (I) from an acid addi-tion salt thereof, or converting an acid addition salt of a : base of the general formula (I) in-to ano-ther acid addi-tion salt.
The reac-tion of the compounds of the general for-mulae (II) and (IIa), respectively, with hydra7ine ~ ~ 1! 6'~ 3 ~ ~ ~ J
derivatives of the general formula (III) is carried ou-t in a solvent inert toward the reactants. For this purpose pre-ferably methanol, 2-propanol, benzene or dimethyl sulfo~id are used. The reaction is performed at a temperature of 0 to 190 C, preferably between 20 and 110 C. The reaction is op-tionally carried ou-t in the presence of a base, pre-ferably an organic base.
The isomerisation of the compounds of the general formula (Ia) into compounds of the general formulae (Ib), (Ic) and (Id) can be carried out in melt or by thermic rearrangenent in a polar or dipolar aprotic solvent, pre-ferably in acetic acid or dime-thylformamide, a-t a temperature between 50 C and 250 C, preferably a-t a temperature of lOO to 190 C. During the reaction a mixture of the compounds of the general formulae (Ib)~
(Ic) and (Id) is produced, which can be separated into the individual isomers by methods known per se, e.g. by chro-; matography or fractional crystallization.
The reaction of the compounds of the general for-mulae (IV) and (V) can be performed in a polar solvent,preferably in an aqueous methanol solution, dimethylform-amide or dimethyl sulfoxide, at a -temperature between 0 and 190 C, preferably at a temperature of 50 to 160 C.
The compounds of the general formula (I) obtained in form of a base can be converted into acid addition salts by methods known per se. For this purpose the free bases are reacted with the corresponding acid in an inert solvent.
The triazolyl esters of the general formula (II) used as starting ma-terials are known compounds or can be produced on the analogy of known compounds (US patent specification No. 3,686,301, DD pa-tent specification No.
105,~97).
The hydrazine derivatives of the general formula (III) are also known compounds (Belsteins Handbuch der Or-~ J~
_9_ ganischen Chemie 4, 546, Verlag Springer, Berlin, 1922;Ullmann: Encyklopadie dEr Technischen ~hemie 13, p. 95, Verlag Chemie Weinheim, 1977).
The carbohydrazide and thiocarbohydrazide of the general formula (IV) are commercially available products.
The compounds o~ the general formula (V) are also commercial products or can be prepared as described in Hungarian patent specification No. 184,743.
The compounds of the general formula (I) are only very slightly toxic and show excellent biological proper-ties. They exert antianginal, tranquillant-sedative, car-diovascular, acid secretion inhibiting, gastric ulcer in-hibiting and antimicrobial ef~ec-ts.
The ac-tivity of the compounds of the general for-mula (I) has been examined by the following tests.
1. ~ntianginal effect Method: Nieschulz, E., Popendiker, K. and Hoffmann, I., Arzneimittel-Forschung, 5, 680 (1955) The -test was carried ou-t on rats weighing 180 to 220 9. The animals were narcotised with chloralese-ure-thane (70 - 700 mg/kg ip.). The ECG was registered with needle electrodes in standard II leading. The experimen-tal coro-naria insufficiency was induced with vasopressin (1 NE/kg ; 25 i.v.). The height of wave T was measured before and after the administration of vasopressin in both the control and treated groups. Test compounds were administered intra-venously 2 minutes prior to the trea-tmen-t with vasopressin The results are summarized in Table I.
Table I
Antianginal e~fect Test compound ED50 mg/kg (Example No.) (iv.) :
..
' ` ' AJ
-17 0.84 Prenylamine 6.5 2. Motility inhibiting activity Method: Borsy, J., Csanyi, E., Lfizar, I.: Arch. Int.
Pharmacodyn. 124, 1-2 (1960) The tests were performed on mice. Groups consisting of 3 mice each were trated perorally with different doses of the compounds to be tested. One hour after -the admi-nistration the test animals were placed in a Dews equip-ment. In this equipment the number of interruptions of ~; 15 infrared beam within 30 minutes was counted. The results :~i obtained are shown in Table II.
:, ` Table II
Mo-tility inhibiting ef~ect Compound LD50 Therapeutical ~ (Example No.) mg/kg p.o. index - 1 100 ~ 10 17 70 ~ 5 - Meprobamate270 4.1 3. Acute toxicity on mice Method: Litchfield, J.T., Wilcoxon, ~.W.: Pharmacol. Exp.
Ther., 96, 99 (1949) White mice belonging -to the CFLP strain (body weight 18 to 22 9, both male and female) were used, 6 animals for each dose. The test compounds were administered orally in a volume of 20 ml/kg. After treatment the animals ' ' , ~ jJ ,~ ~? I , ; 1 were observed for a period of 14 days. The mice ~ere kep-t in a plastic cage at room temperature. The animals get tap wa-ter and s-tandard mouse fodder ad libi-tum. The toxicity data were determined with the aid of the method of Litchfield and Wilcoxon. The results are summarized in Table III.
Table III
Acute toxicity on mice Example No. Ld50 mg/kg p.O.
16 lO00 l ~ lO00 9 lO00 The above data show that certain representatives of the compounds according to the invention are 8 or 10 times as effective on the antianginal test as the re-ference substance Prenylamine and are superior as motility inhibi-tors to the reference compound Meprobamate. At the sametime they are only very slightly toxic.
In addition, the compounds according to the in-vention possess valuable antimicrobial effect, especially against nonfermenting Gram-negative bacteria strains. So the compound of Example 9 inhibits, determined by agar diffusion method in a concentration of 500 /ug/hole, the bacteria strains listed in Table IV.
:
` Table IV
An~timicrobial e~ffect of the compound according -to Ex. 9 .
~ J~ 5 Microbe strain HNCMB+ Inhibition (%) deposition number Salmonella enteritidis 10091 17 Shigella sonnei 20046 19 Acinetobacter calcoaceticus 150001 20 Pseudomonas aeruginosa 170006 14 Pseudomonas stutzeri 173008 25 Alcaligenea faecalis 140001 23 HNCMB = Hungarian National Collection of Medical Bacteria 4. Stomach-secretion and ulcus tes-ts on mice Method: 5hay, H., Komarov, S.A., ~els. 5.5., Meranze, O., Gruenstein, M., Siplet, H.: Gas-troenterology 5, 45 (1945); Adami, E., Marazzi-Ubertti, E., Tirba, C.: Arch. Int. Pharmacodyn. 147, 113 (1964).
Starved wistar mice of 150-250 9 body weight were used, 4 male and 4 female animals for each dose. On the day of the experiment the pylorus of the animals was ligatured under ether narcosis. The doses of the test compounds were administered per os, 3 hours before the operation. The control groups were treated with the carrier in identical way. 4 hours after -the operation the 'animals were over-narcotized wi-th ether, their stomach was removed, the stomach contents were separa-ted and after centrifugation the volume of -the gas-tric juices was - measured, then their free-acid content and to-tal acidity, resp., were determined by titra-tion wi-th 0.1 N NaDH sol-ution. The changes of the gastric mucous membrane were investigated macroscopically and characteri~ed by an ulcus `;
J t ,) ? ,'~
index determined with -the aid of the punctuation method of Adami and coworkers.
The results obtained are shown in Table V.
Table V
Gastric-secretion- and ulcus-inhibiting effects on mice Example Dose Inhibition related to the cnntrol in %
No. mglkg Gastric Free Total Ulcus po. juice acid acidity index :
Cimetidine50 22 24 15 18 :
The above data unambiguously show that the effect of the compounds according to the invention reach or even surpasse that of Cimetidine but their toxicity is slight and due to the differing structures they are exempt from the very unfavcurable side-effect of causing impotency of Cimetidine.
According to a ~urther aspect of the present in-vention there are provided pharmaceutical compositions comprising as active ingredient at least one compound of the general formula (I) or a pharmaceutically acceptable -: acid addition salt thereof in admixture with suitable : 30 inert solid or liquid pharmaceutical carriers.
The pharmaceutical compositions of the present in-vention can be prepared by methods.known ~ se by ad-mixing the active ingredient with suitable inert solid or liquid carriers and bringing the mixture to galenic form.
The pharmaceutical compositions of the presen-t in-.- ~ .
vention may be suitable for oral (e.g. tablet, pill, coated pill, dragée, solid or soft gelatine capsule, solution, emulsion or suspension), parenteral (e.g.
injection solution) or rectal (e.g. suppository) admi-nistration.
As carrier for the preparation of tablets, coa-ted tablets, dragées and solid gelatine capsules e.g. lactose, corn starch, potatoe starch, talc, magnesium carbonate, magnesium stearate, calcium carbonate, stearic acid or the salts thereof, etc. can be used. As carrier for the soft gelatine capsules e.g. vegetable oils, :Eats, waxes or po-lyols of suitable consistency can be used. As carriers for the solutions and syrups e.g. water polyols (polye-thy].ene glycol),saccharose or glucose can be used. The injection solutions can comprise e~g. water alcohols, polyols, glycerol or vegetable oils as carrier. The suppositories can be prepared with the aid of e.g. oils, waxes, fats or polyols of suitable consistency.
In addition, the pharmaceutical formulations may comprise auxiliaries usually applied in pharmaceutical industry, e.g. wetting, sweetening agents, aroma substances, salts causing the change of osmotic pressure, buffers, etc.
The compounds of the general formula (I) can prefer-ably be used in -therapy orally in the form of tablets or capsules. Especially preferred are the capsules or tablets comprising 0.5 to 500 mg of active ingredient The daily dose of the compounds of the general for-mula (I) can vary within wide ranges depending on several factors, e.g. on the activity of the active ingredient, the patient`s condition and age, the severity of the disease, etc. The oral dose is generally 2 to 5000 mg/day, preferably 5 to 1000 mg/day. It has to be stressed tha-t the above dose is only of informative character and the administered dose must always be determined by the , . . . ' ,'. . ' .
physician thera~eutist.
AccQrding to a further aspect of the present in-vention there is provided the use of the compounds of the general formula (I) or pharmaceutically acceptable salts thereof for the preparation of pharmaceutical compositions having par-ticularly antianginal and/or gas-tric ulcer in-hibiting effects.
According to a still fur-ther aspect of the present invention there is provided a method for antianginal and/or gastric ulcer inhibiting treatment, which comprises ad-ministering to the patient an effective amount of a com-pound of the general formula tI) OL' a pharmaceutically acceptable salt thereof.
The invention is fur-ther il-lustra-ted by the aid of the following Examples of non-limiting character.
Example 1 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4--triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. Then the separated crys-tals are filtered off and recrystallized from benzene.
Yield: 15.0 q (59 %) M.p.: 144 to 146 C.
E~ample 2 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)-N'-methyl-carbothiohydrazide One proceeds as described in Example 1, with the difference that the mother liquor obtained after filtering the reaction mixture is allowed to stand for 2 days. The separated crystals are then filtered off and recrystallized . .
, . . -~. . . j . .
~ J ~ $ e~ ?~
from 2-propanol.
Yield: 3.8 9 (15 %) M.p.: 125 to 126 C.
Example 3 1-(5-Amino-3-morpholino-lH-192,4-triazol-l-yl)-N-methyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 100 ml 10 of dimethyl sulfoxide, in the presence of 5.7 ml (0.11 mole) of methylhydrazine for 8 hours at room temperature.
The reaction rnixture is poured onto 100 ml of water, the separated crystals are filtered off and recrystallized from benzene.
15 Yield: 8.3 9 (38 %) M.p.: 144 to 146 C.
Example 4 - 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl3-N-me-thyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio~
lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separa-ted crystals are filtered off and recrystallized from benzene.
Yield: 11.8 g (54 %) M.p.: 164 to 166 C.
:
Example 5 1-(5-Amino-3-methylthio-lH-1,2,4-triaznl-1-yl)-N-methyl-oarbothiohydrazide 22.0 g (0.1 mole) of methyl (5-amino-3-methyl-thio-1_-1,2,4-triazol-1-yl)carbodithioate are stirred in 400 ml of 2-propanol, in the presence of 6.9 ml (0.13 mole) of ~ - -, . .
.
.
` ~ d J '~
$ æY
methylhydrazine for 8 hours at room -temperature. The separated crystals are filtered off and recrys-tallized from benzene.
Yield: 10.5 9 (4B %) M.p.: 164 to 166 C.
Example 6 1-~5-Amino-3-me-thylthio-lH-1,2~4-triazol-1-yl)-N-me-thyl-carbothiohydrazide 22.0 9 (0.1 mole) of me-thyl (5-amino-3-me-thylthio-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 200 ml of benzene, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 8 hours a-t room temperature. The separated crystals are fil-tered off and recrystallized from benzene.
Yield: 8.9 9 (41 ~) M.p.: 164 to 166 C.
.
Example 7 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 11.8 9 (54 %) M.p.: 164 to 166 C.
Example 8 1-(5-Amino-3-methylthio-lH-1,2,4-triazol-1-yl~-N-methyl-carbothiohydrazide 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1~2,4-triazol-1-yl)carbodithioate are boiled in 140 ml . .
. . .
:, .
~ ~; 2 ~
of methanol, in the presence of 5.7 ml (0.11 mole) of methylhydrazine for 1 hour. The reac-tion mixture is then evaporated to 70 ml, the separated crystals are filtered off and recrystallized from benzene.
Yield: 8.3 9 (3a %) M.p.: 164 to 166 C.
Example 9 1-~5-Amino-3-N-methylpiperazinyl)-lH-1,2 9 4-triazol-l-yl~-N-methyl-carbothiohydrazide 27.2 g (0.1 mole) of methyl (5-amino-3-N-methylpi-perazinyl-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours. The reac-tion mix-ture is evaporated to dryness in vacuo. The oily product thus obtained crystallises upon adding of 2-propanol. The se-para-ted crystals are filtered off and recrystallized from acetonitrile.
Yield: 13 9 (48 %) M.p.: 150 to 152 C.
Example 10 1-(5-Amino-3-dimethylamino-lH-1,2,4-triazol-1-yl)-N-me~hyl-carbothiohydrazide 21.7 g (0.1 mole) of methyl. (5-amino-3-dimethyl-amino-1~1-1,2,4-triazol-1-yl)carbodithioate are stirred in 100 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at roorn temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 12.2 9 (51 %) M.p.: 165 ta 167 C.
Example 11 1-(5-Ami~o-3-mo~pholirlo-4H-1,2,~ riazol-4-yl)-N-. ~
, ', ~, ' ' ' ~- , . ' ~
r methyl-carbothiohydrazide 25.5 9 (0.1 mole) of 1-(5-amino-3-morpholino-lH-`- 1,2,4-triazol-1-yl)~N-methyl-carbodithiohydrazide areboiled in 75 ml af acetic acid for 30 minutes, under stirring. The reaction mixture is cooled, the separated crystals are filtered off and recrystallized from ; methanol.
Yield: 10.5 9 (41 %) M.p.: 239 to 240 C.
Example 12 1-(5-Amino-3-morpholino-2H-1,2,4-triazol-2-yl)-N-methyl-carbothiohydrazide On proceeding as described in Example 11 the mother liquor ob-tained after filtering the reaction mixture is evaporated to dryness and the residue is recrys-tallized first from an aqueous ethanol solution then from aceto-nitrile.
Yield: 6.12 9 (24 %) M.p.: 258 to 259 C.
.
Example 13 2-Methyl-4-(3-morpholino-lH-1,2,4--triazol-5-yl) thiosemicarbazide 25.7 9 (0.1 mole) of methyl (3-morpholino-2H-1,2,4-~ triazol-5-yl)dithiocarbaminate are boiled in 250 ml of ;~ methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 2 hours, under s-tirring. The separated crystals are filtered off and recrystallized from methanol.
Yield: 17.34 9 (68 %) M.p.: 211 to 212 C.
Exa~ple 14 (5-Benzylamino-3-morpholino-lH-1,2,4-triazol-1-~5 yl)-N-me-thyl-carbothiohydrazide 34.9 9 (0.1 mole) o~ methyl (5-benzylamino-3-, ~, , ', 2 ~ 2 ~ 'J
morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are stirred in 150 ml of methanol, in the presence of 6.9 ml (0.13 mole) of methylhydrazine for 4 hours at room temperature. The separated crystals are filtered off and recrystallized from benzene.
Yield: 22.5 9 (63 %) M.p.: 133 to 134 C.
Example 15 1-~5-Benzylamino-3-morpholino-lH-1,2,4-triazol 1-yl)-N'-methyl-carbothiohydrazide One proceeds as described in Example 14, wlth the difference that the mother liquor obtained after filtra-tion is allowed to stand for 2 days. Then the separated crystals are filtered off and recrystallized from a mixture of n-hexane and ether.
Yield: 5.6 9 (16 %) M.p.: 86 to 87 C.
Example 16 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl) carbothiohydrazide A mixture of 25.7 g (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate, 2ûO ml of methanol and 6 ml (0.12 mole) o~ a 99 % hydrazine hydrate solution is stirred for 4 hours at room temperature. Then it is filtered and the ~thus-obtained crystals are recrystallized from a mixture of dime-thyl-formamide and acetonitrile.
Yield: 20.9 9 (86 %) M.p.: 180 to 18Z C.
Example 17 1-~5-Amino-3-me-thylthio-lH-1,2,4-triazol-1-yl) carbothioh~drazide . ;
.
` . ~
':
~ ~ ~ C,,~ ~; ?'~ rJ
A mixture of 22.0 9 (0.1 mole) of methyl (5-amino-3-methylthio-lH-1,2,4-triazol-1-yl)carbodithioate, 200 ml of methanol and 6 ml (0.12 mole) of a 99 % hydrazine hydrate solution is stirred for 4 hours at room J
temperature. Then it is filtered and the precipitated crystals are recrystallized from dimethyl~ormamide.
Yield: 17.3 9 (85 %) M.p.: 185 to 186 C.
Example 18 1-(5-Amino-~-methylthio-lH-1,2,4-triaznl-1-yl) carbo-thiohydrazide To a mixture of 10.6 9 (0.1 mole) of thiocarbohydrazide and 130 ml of water a solution of 15 9 (0.102 mole) of dimethyl (N-cyanocarbonimidodithioate) in 65 ml of methanol is added, and the reaction mixture is m boiled for 2 hours. Then it is cooled, the precipitated crystals are filtered off and recrystallized from dime-thylformamide.
Yield: 17.8 9 (86 %) M.p.: 185 to 186 C.
Example 19 1-~5-Amino-~-(N-methylpiperazinyl~-lH-1,2,4-triazol-l-yl~carbothiohydrazide 27.2 9 (0.1 mole) of methyl ~5-amino-3-(N-methyl-~ piperazinyl)-lH-1,2,4-triazol-1-yl)carbodithioate are -~ stirred in 150 ml of methanol, in the presence of 6.9 ml ~0.13 mole) of hydrazine hydrate for 4 hours at room temperature. Then the reaction mixture is cooled and the -thus-obtained crystals are recrystallized from dimethyl-formamide.
Yield: 24.5 9 (94 %) M.p.: 194 to 196 C.
'~
, .
~ - :
$ i~ ~
Preparation of the trihydrochloride salt:
1 9 of base ob-tained as described above is dissolved in 5 ml of hot dimethylformamide, and the solution is acidified to pH=2 with a 15 % (v/v) solution o~ hydrogen chloride in isopropanol. The separated product is filtered off and washed with isopropanol.
Yield: 0.9 9 M.p.: 158 to 160 C.
Example 20 1-(5-Amino-3-morphnlino-lH-1,2,4-triazol-1-yl)-N,N'-dimethyl-carbothiohydrazide 25.7 9 (0.1 mole) of methyl (5-amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are boiled in 1~0 ml of methanol, in the presence of 14.6 ml (0.12 mole) of N,N'-dimethylhydrazine dihydrochloride and 46 ml of tri-ethylamine for 16 hours. Then the reaction mixture is evaporated to dryness in vacuo. 400 ml of water are added to the residue and the aqueous phase is extracted three times with 200 ml of chloroform. The organic phase thus obtained is washed two times with 200 ml of water, dried over magnesium sulfate and evaporated in vacuo. The precipitated crystals are suspended in diethyl ether and fil-tered off.
Yield: 11.3 y (43 %) M.p.: 127 -to 128 C.
Example ~1 1-(5-Amino-3-diallylamino-lH-1,2,4-triazol-1-yl)-N-me~hyl-carbothiohydrazide 4.2 9 (0.0156 mole) of methyl (5-amino-3-diallyl-amino-lH-1,2,4-triazol-1-yl)carbodithioa-te and 1~38 ml (0.026 mole) of methylhydrazine are reacted in 20 ml of methanol at room temperature for 8 hours. Upon adding 10 ml of water to the thus-ob-tained solution 1.2 9 (29 %) of ' pure 1-(5-amino-3-diallylamino-lH-1,2,4--triazol-1-yl)-N-methyl-carbothiohydrazide get separated. M.p.: 86 to B8 C. When evaporating the mother liquor further 2 9 of crystalline product are obtained which melt at 85 to 88 C
So the total yield amounts to 77 %.
Example 22 1-(5-Benzylamino-3-morpholino-lH-1,2,4-triazol-1-yl)-N,N'-dimethyl-carbothiohydrazide 6.9B 9 (0.02 mole) of methyl (5-benzylamino-3-morpholino-lH-1,2,4-triazol-1-yl)carbodithioate are boiled `in 50 ml of methanol, in the presence of 2.92 ml (0.024 mole) of N,N'-dimethylhydrazine dihydrochloride and 9.4 ml of triethylamine for 8 hours. Then the reaction mixture is evaporated to dryness in vacuo. 100 ml of water are added to -the residue and the aqueous phase is extracted three times with 50 ml of chloroform. The thus-obtained organic phase is washed twice with 50 ml of water, dried over magnesillm sulfate and evapora-ted to dryness in vacuo. The thus-obtained crystals are suspended in diethyl e-ther and filtered off.
Yield: 3.25 9 (45 %) M.p.: 66 to 68 C.
Exa~ple 23 5-(4-Dimethylaminobenzylamino)-3-morpholino-lH-1,2,4-triazol-1-yl~carbothiohydrazide 1.96 9 (0 005 mole) of methyl ~5-(4-dimethylamino-benzylamino)-3-morpholino-lH-1,2,4-triazol-1-yl~carbodi-thioate are boiled in 20 ml of methanol, in the presence of 0.3 ml of hydrazine hydrate for 1 hour, under stirring.
The reaction mixture is cooled, the separated crystals are filtered off and recrystallized from methanol.
Yield: 1.43 9 (a3 %) M.p.: 127 to 129 C.
-ft ~ r~ r r Example 24 1-(4-Chlorobenzylamino-3-morpholino-lH-1,2,4-triazol-l-yl)-N-methyl-carbothiohydrazide 38.2 9 (0.1 mole) of me-thyl /5-(4-chlorobenzyl-amino)-3-morpholino-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 700 ml of methanol, in the presence of 6.4 ml (0.12 mole) of methylhydrazine for 1 hour, under stirring. The reaction mixture is cooled, the precipitated crystals are filtered off and recrystallized -from a mixture of benzene and cyclohexane.
Yield: 23.2 9 (61 %) M.p.: 152 to 154 C.
Example 25 1-/5-(4-chlorobenzylamino)-3-me-thylthio-lH-1,2,4-triazol-l-yltcarbothiohydrazide 17.2 9 (0.05 mole) of methyl /5-(4-chlorobenzyl-amino)-3-methylthio-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 200 ml of methanol, in -the presence of 6 ml of hydrazine hydrate for 0.5 hour, under stirring. The -~ reaction mixture is cooled, the separated crystals are filtered off and recrystallized from methanol.
Yield: 13.8 9 (84 %) M.p.: 140 to 142 C.
Example 26 1-(5-Benzylamino-3-morpholino-lH 1,2,4-triazQl-l~
yl)carbothiohydrazide 3.49 9 (0.01 mole) of methyl (5-benzylamino-3-mor-pholino-lH-1,2,4-triazol-1-yl)carbodi-thioate are stirred in 50 ml of methanol, in the presence of 0.64 ml (0.013 mole) of hydrazine hydrate for 4 hours, at room temperature.
The separated crystals are filtered off and recrystallized from methanol.
Yield: 2.84 9 (85 O) - . . :
..... ........ ........ ... ......... .... ..... ... ........ ............... .... ... ... ... ........... ,:
- ~ .
. : , ' ~: , -- , ~ .
,2 M.p.: 141 to 143 C.
Example 27 1-/5-(4-Chlorobenzylamino)-3-morpholino-lH-1,2,4-triazol-l-yl/carbothiohydrazide 1.9 9 (0.005 mole) of methyl /5-(4-chlorobenzyl-amino)-3-morpholino-lH-1,2,4-triazol-1-yl/carbodithioate are boiled in 40 ml of methanol, in the presence of 0.3 ml (0.0058 mole) of hydrazine hydrate for 1 hour, under stirring. Then the separated crystals are fil-tered off and recrystallized from methanol.
Yield: 2.64 9 (71 %) M.p.: 169 to 171 C.
Example 28 1-(3~5-Dîamino-lH-1,274-triazol-l-yl)-N-methyl-carbothiohydrazide 0.76 9 ~0.004 mole) of methyl (3,5-diamino-lH-1,2,4-triazol-1-yl)-N-methyl-carbodithioate is stirred in 75 ml of methanol, in the presence of 0.29 ml of hydrazine hydrate for 1 hour at room temperature. The separated crystals are filtered off and recrystallized from 2-propa-nol.
Yield: 0.68 9 (73 %) M.p.: 1~4 to 186 C.
Example 29 1-(5-Amino-3-diallyla~ino-lH-1~2,4-triazol-1-yl3 carbothiohydrazide 26.90 9 (0.1 mole) of methyl-(5-amino-3-diallyl-amino-lH-1,2,4--triazol-1-yl)carbodi-thioate are boiled in 200 ml of methanol, in the presence of 6 ml of hydrazine hydrate for 1 hour, under stirring. The precipitated crystals are filtered off and recrystallized from benzene~
Yield: 20.64 9 (82 %) : . :
: , , .
2~
M.p.: 142 to 144 C.
Example 30 1-(5-Amino-3-methyl-thio-lH-1,2,4-triazol-1-yl)-carbo-thiohydrazide To a mixture of 9 9 (0.1 mole) of carbohydrazide and 160 ml of methanol a solution of 14.6 9 (0.102 mole) of dimethyl N-cyanocarbonimidodithioate in 100 ml of me-thanol is added under stirring. The reaction mixture is boiled for 3 hours, then it is cooled, the separated crystals are filtered off and recrystallized from metha-nol.
Yield: 15.6 9 (83 %) M.p.: 163 to 164 C.
Example 31 1-(5-Amino-2H-1,2,4-triazQl-2.-yl)-N-methyl-carbothiohydrazide 0.61 9 (0.0035 mole) of 1-(5-amino-2H-1,2,4-tri-azol-2-yl)carbodithioate is stirred in lU ml of me-thanol, in the presence of 0.184 ml (0.004 mole) of methyl-~; hydrazine for 2 hours, at room temperature. The ; solution is evaporated to dryness in vacuo and the residue is recrystallized from isopropanol.
Yield: 0.4 9 (66 %) M.p.: 85 to 90 C.
Example 32 Tablets having the following composition are prepared by methods known per se of the pharmaceutical industry:
:
Compsnents Amount, g/tablet 1-(5-Amino-3-morpholino-lH-35 1,2,4-triazol-1-yl)carbothio-- . . .: .
' ' - - ' : ~: ' .. . .
r~
hydrazide 5 Lactose 1~.5 Po-tato starch 13.0 Polyvinylpyrrolidone 6.8 5 Stearic acid 2.7 Talc 4.0 Total weight 50.0 9 Example 33 Ointments having the following composition are prepared by me-thods known per se of the pharmaceutical industry:
Components Amount 15 1-(5-Amino-3-morpholino-lH-1 t 2,4-triazol-1-yl)-N-methyl-carbothiohydrazide 500 mg : Unguentum hydrophilicium nonbonicum10 9 The active ingredient is in the outer phase of the ointment, in dissolved state.
Example 34 Suppositories having the following compositiun are prepared by methods known per se of -the pharmaceutical industry:
Components Amnunt 3 mg/suppository 1-~5-Amino-3-morpholino-lH-1,2,4-triazol-1-yl)carbothio-.~ hydrazide 100 Lecithin 48 Cera alba 96 Cocoa butter 1870 : 35 .~
.
rl Distilled ~ater 386 Total weight 2500 mg Example 35 `: 5 Capsules having the following composition are ; prepared by methods known per se of the pharmaceutical industry:
Components Amount, mg/capsule 1-(5-Amino-3-morpholino-lH-1,2,4-triazol-l-yl)carbothio-hydrazide 50 Lactose Potato starch lO
Magnesium stearate Total weight 180 mg-:.
~`
:.:
~, ; :
:~ 30 :
~'Z
' .
' ~
,:-.
.
- , , :
~ : : ?
Claims (15)
1. Triazolyl hydrazide derivatives of the general formula (I) and pharmaceutically acceptable salts thereof, (I) wherein Q represents hydrogen or a heterocyclic group optionally substituted by a C1-4 alkyl group; or a group of the formula SR1, wherein C1-4 alkyl or phenyl-(C1-4 alkyl), or a group of the formula NR2R3, wherein R2 and R3 each represent hydrogen, straight or branched chained C1-6 alkyl or C2-6 alkenyl;
Z represents hydrogen or a group of the formula (C=X)-(N-R4)-NR5R6, wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or C1-4 alkyl;
R7 denotes hydrogen, C1-4 alkyl or phenyl-(C1-4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6.
Z represents hydrogen or a group of the formula (C=X)-(N-R4)-NR5R6, wherein X stands for oxygen or sulfur, R4, R5 and R6 each stand for hydrogen or C1-4 alkyl;
R7 denotes hydrogen, C1-4 alkyl or phenyl-(C1-4 alkyl) optionally substituted by one or more halogen atom(s), R8 stands for hydrogen or a group of the formula -(C=X)-(N-R4)-NR5R6, wherein X, R4, R5 and R6 are as stated above, with the proviso that if Z represents a group of the formula -(C=X)-(N-R4)-NR5R6, R8 stands for hydrogen, and if Z represents hydrogen, R8 stands for a group of the formula (C=X)-(N-R4)-NR5R6.
2. Compounds as claimed in claim 1, wherein Q
represents morpholino, methylthio, dimethylamino or N-me-thyl-piperazinyl and R7 and R8 each stand for hydrogen, and pharmaceutically acceptable acid addition salts thereof.
represents morpholino, methylthio, dimethylamino or N-me-thyl-piperazinyl and R7 and R8 each stand for hydrogen, and pharmaceutically acceptable acid addition salts thereof.
3. The following compounds of the general formula (I) according to claim 1:
1-(5-amino-3-morpholino-1H-1,2,4-triazol-1-yl)-N-methyl-carbo-thiohydrazide, 1-(5-amino-3-methylthio-1H-1,2,4-triazol-1-yl)carbo-thiohydrazide, 1-(5-amino-3-N-methylpiperazinyl-1H-1,2,4-triazol-1-yl)-carbothiohydrazide, 1-(5-amino-3-morpholino-1H-1,2,4-triazol-1-yl)-N,N'-di-methyl-carbothiohydrazide, and pharmaceutically acceptable acid addition salts thereof.
1-(5-amino-3-morpholino-1H-1,2,4-triazol-1-yl)-N-methyl-carbo-thiohydrazide, 1-(5-amino-3-methylthio-1H-1,2,4-triazol-1-yl)carbo-thiohydrazide, 1-(5-amino-3-N-methylpiperazinyl-1H-1,2,4-triazol-1-yl)-carbothiohydrazide, 1-(5-amino-3-morpholino-1H-1,2,4-triazol-1-yl)-N,N'-di-methyl-carbothiohydrazide, and pharmaceutically acceptable acid addition salts thereof.
4. A process for the preparation of compounds of the general formula (I), w h i c h c o m p r i s e s a) reacting a triazolyl ester of the general formula (II), (II) wherein Y represents hydrogen or a group of the formula (C=X)-XR9, wherein X is as stated above, R9 is C1-4 alkyl or phenyl optionally substituted by one or more halogen atom(s), R7 and Q are as defined above, R10 represents hydrogen or a group of the formula (C=X)-XR9, with the proviso that if Y stands for hydrogen, R10 represents a group of the formula (C=X)-XR9, wherein X and R9 are as stated above, and if Y stands for a group of the formula (C-X)-XR9, R10 represents hydrogen, with a hydrazine derivative of the general formula (III), (III) wherein R4, R5 and R6 are as stated above; or b) for the preparation of isomeric compounds of the gen-eral formulae (Ib), (Ic) and (Id) representing subgroups of the compounds of the general formula (I), (Ib) (Ic) (Id) reacting a triazolyl ester of the general formula (IIa), (IIa) wherein R7, R9, X and Q are as stated above, with a hydrazine derivative of the general formula (III), heating the thus-obtained compound of the general for-mula (Ia), (Ia) and separating the isomers from each other by methods known per se; or c) for the preparation of isomeric compounds of the gen-eral formulae (Ib), (Ic) and (Id) representing subgroups of the compounds of the general formula (I), heating a compound of the general formula (Ia) and separating the isomers from the thus-obtained product by methods known per se; or d) for the preparation of compounds of the general formula (Ia) representing a subgroup of the compounds of the general formula (I), wherein R4, R5, R6 and R7 repre-sent hydrogen and Q stands for a group of the formula SR11, wherein R11 denotes C1-4 alkyl or phenyl-(C1-4 alkyl) optionally bearing one or more halogen, C1-4 al-kyl or nitro substituent(s), reacting a compound of the general formula (IV), (IV) wherein X is as stated above, with a compound of the general formula (V), (V) wherein R11 is as stated above;
and, if desired, converting the compound of the general formula (I) thus-obtained into a pharmaceutically acceptable acid addition salt thereof or setting free a base of the general formula (I) from an acid addition salt thereof, or converting an acid addition salt of a base of the general formula (I) into another acid addi-tion salt.
and, if desired, converting the compound of the general formula (I) thus-obtained into a pharmaceutically acceptable acid addition salt thereof or setting free a base of the general formula (I) from an acid addition salt thereof, or converting an acid addition salt of a base of the general formula (I) into another acid addi-tion salt.
5. A process according to variants a) and b) of claim 4, w h i c h c o m p r i s e s carrying out the reaction in melt or in a solvent inert toward the reactants, preferably in methanol, 2-propanol, dimethyl sulfoxide or benzene, optionally in the presence of a base.
6. A process as claimed in claim 5, w h i c h c o m p r i s e s carrying out the reaction at a temperature between 0 °C and 190 °C, preferably between 20 °C and 110 °C.
7. A process according to claim 5 or 6, w h i c h c o m p r i s e s carrying out the reaction in the presence of an organic base, preferably triethyl-amine.
8. A process according to variants b) and c) of claim 4, w h i c h c o m p r i s e s heating the com-pound of the general formula (Ia) in melt or in a solvent, preferably in a protic or dipolar aprotic solvent.
9. A process according to variants b) and c) of claim 4, and according to claim 8 or 9, w h i c h c o m p r i s e s carrying out the isomerisation of the compound of the general formula (Ia) at a temperature between 50 °C and 250 °C, preferably between 100 °C and 190 °C.
10. A process according to variant d) of claim 4, w h i c h c o m p r i s e s carrying out the reaction in a protic or dipolar aprotic solvent, preferably in an aqueous methanol solution or dimethylformamide.
11. A process according to variant d) of claim 4 and according to claim 10, w h i c h c o m p r i s e s carrying out the reaction at a temperature between 0 °C
and 190 °C, preferably between 50 °C and 160 °C.
and 190 °C, preferably between 50 °C and 160 °C.
12. Pharmaceutical compositions c o m p r i s i n g as active ingredient at least one compound of the general formula (I) or a pharmaceutically acceptable salt thereof in admixture with suitable inert solid or liquid pharma-ceutical carriers.
13. A process for the preparation of pharmaceutical compositions according to claim 12, w h i c h c o m p r i s e s admixing a compound of the general formula (I) or a pharmaceutically acceptable acid addition salt thereof with suitable inert solid or liquid thera-peutical carriers.
14. Use of compounds of the general formula (I) or pharmaceutically acceptable acid addition salts thereof for the preparation of pharmaceutical compositions having particularly antianginal and/or gastric ulcer inhibiting effect(s).
15. Method of antianginal and/or gastric ulcer in-hibiting treatment, w h i c h c o m p r i s e s ad-ministering to a patient an effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU895426A HU895426D0 (en) | 1989-10-25 | 1989-10-25 | Process for the preparation of dihydro-triazolo-tetrazepine derivatives |
HU5428/1989 | 1989-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2028557A1 true CA2028557A1 (en) | 1991-04-26 |
Family
ID=10970287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2028557 Abandoned CA2028557A1 (en) | 1989-10-25 | 1990-10-25 | Triazolyl hydrazide derivatives and process for their preparation |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2028557A1 (en) |
HU (1) | HU895426D0 (en) |
-
1989
- 1989-10-25 HU HU895426A patent/HU895426D0/en unknown
-
1990
- 1990-10-25 CA CA 2028557 patent/CA2028557A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HU895426D0 (en) | 1990-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920006781B1 (en) | Method of preparing for dihydropyridazinone derivatives | |
US4616025A (en) | Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof | |
KR19980702891A (en) | 6-substituted pyrazolo [3,4-di] pyrimidin-4-ones and compositions thereof and methods of use thereof | |
ZA200201485B (en) | N-Heterocyclic derivatives as NOS inhibitors. | |
FR2643903A1 (en) | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS | |
TW470742B (en) | Benzimidazole derivatives, preparation and pharmaceutical compositions thereof | |
NO159272B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF NEW THERAPEUTIC ACTIVE DIHYDROPYRIDINES. | |
EP0425283B1 (en) | Novel triazolyl hydrazide derivatives and process for their preparation | |
US4782056A (en) | 2-phenylhexahydro-1,2,4-triazine-3-,5-diones | |
US4767769A (en) | Antiulcer benzimidazole derivatives | |
CS262690B2 (en) | Process for preparing 1-/hydroxystyryl/-5h-2,3-benzodiazepines | |
US5523310A (en) | 1,2,3-triazole derivatives | |
CA2028557A1 (en) | Triazolyl hydrazide derivatives and process for their preparation | |
US4152440A (en) | Novel derivatives of imidazole, and pharmaceutical compositions containing them | |
US4450160A (en) | 1,2-Dihydropyrido[3,4-b]-pyrazines and method and intermediates for preparing same | |
US4213986A (en) | Novel derivatives of imidazole and pharmaceutical compositions containing them and method of use | |
US5071849A (en) | Dihydropyrimidothiazine derivatives | |
US5023255A (en) | Chemical compounds | |
EP0425282A2 (en) | Triazolo derivatives and process for their preparation | |
CA1141765A (en) | Benzimidazole derivatives | |
US5276030A (en) | Triazolyl thioamide derivates | |
US4521534A (en) | Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use | |
US4600716A (en) | 1,2-dihydropyrido[3,4-b]pyrazines | |
US3954981A (en) | Triazolocycloalkylhydrothiadiazine derivatives | |
US4645840A (en) | Intermediates for preparing 1,2-dihydropyrido[3,4-b]-pyrazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |